Point-of-care test for cervical cancer in LMICs

Sulma I. Mohammed, Wen Ren, Lisa Flowers, Bartek Rajwa, Carla J. Chibwesha, Groesbeck P. Parham, Joseph M.K. Irudayaraj

Research output: Contribution to journalArticle

Abstract

Cervical cancer screening using Papanicolaou's smear test has been highly effective in reducing death from this disease. However, this test is unaffordable in low- and middle-income countries, and its complexity has limited wide-scale uptake. Alternative tests, such as visual inspection with acetic acid or Lugol's iodine and human papillomavirus DNA, are sub-optimal in terms of specificity and sensitivity, thus sensitive and affordable tests with high specificity for on-site reporting are needed. Using proteomics and bioinformatics, we have identified valosin-containing protein (VCP) as differentially expressed between normal specimens and those with cervical intra-epithelial neoplasia grade 2/3 (CIN2/CIN3+) or worse. VCP-specific immunohistochemical staining (validated by a point-of-care technology) provided sensitive (93%) and specific (88%) identification of CIN2/CIN3+ and may serve as a critical biomarker for cervical-cancer screening. Future efforts will focus on further refinements to enhance analytic sensitivity and specificity of our proposed test, as well as on prototype development.

Original languageEnglish (US)
Pages (from-to)18787-18797
Number of pages11
JournalOncotarget
Volume7
Issue number14
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Point-of-Care Systems
Papanicolaou Test
Early Detection of Cancer
Uterine Cervical Neoplasms
Sensitivity and Specificity
Computational Biology
Acetic Acid
Proteomics
Biomarkers
Staining and Labeling
DNA
Neoplasms
CDC48 protein

Keywords

  • Africa
  • Cancer
  • Cervical
  • LMIC
  • Point-of-care

ASJC Scopus subject areas

  • Oncology

Cite this

Mohammed, S. I., Ren, W., Flowers, L., Rajwa, B., Chibwesha, C. J., Parham, G. P., & Irudayaraj, J. M. K. (2016). Point-of-care test for cervical cancer in LMICs. Oncotarget, 7(14), 18787-18797. https://doi.org/10.18632/oncotarget.7709

Point-of-care test for cervical cancer in LMICs. / Mohammed, Sulma I.; Ren, Wen; Flowers, Lisa; Rajwa, Bartek; Chibwesha, Carla J.; Parham, Groesbeck P.; Irudayaraj, Joseph M.K.

In: Oncotarget, Vol. 7, No. 14, 01.01.2016, p. 18787-18797.

Research output: Contribution to journalArticle

Mohammed, SI, Ren, W, Flowers, L, Rajwa, B, Chibwesha, CJ, Parham, GP & Irudayaraj, JMK 2016, 'Point-of-care test for cervical cancer in LMICs', Oncotarget, vol. 7, no. 14, pp. 18787-18797. https://doi.org/10.18632/oncotarget.7709
Mohammed SI, Ren W, Flowers L, Rajwa B, Chibwesha CJ, Parham GP et al. Point-of-care test for cervical cancer in LMICs. Oncotarget. 2016 Jan 1;7(14):18787-18797. https://doi.org/10.18632/oncotarget.7709
Mohammed, Sulma I. ; Ren, Wen ; Flowers, Lisa ; Rajwa, Bartek ; Chibwesha, Carla J. ; Parham, Groesbeck P. ; Irudayaraj, Joseph M.K. / Point-of-care test for cervical cancer in LMICs. In: Oncotarget. 2016 ; Vol. 7, No. 14. pp. 18787-18797.
@article{edd23830d5074c07822b233e661c7237,
title = "Point-of-care test for cervical cancer in LMICs",
abstract = "Cervical cancer screening using Papanicolaou's smear test has been highly effective in reducing death from this disease. However, this test is unaffordable in low- and middle-income countries, and its complexity has limited wide-scale uptake. Alternative tests, such as visual inspection with acetic acid or Lugol's iodine and human papillomavirus DNA, are sub-optimal in terms of specificity and sensitivity, thus sensitive and affordable tests with high specificity for on-site reporting are needed. Using proteomics and bioinformatics, we have identified valosin-containing protein (VCP) as differentially expressed between normal specimens and those with cervical intra-epithelial neoplasia grade 2/3 (CIN2/CIN3+) or worse. VCP-specific immunohistochemical staining (validated by a point-of-care technology) provided sensitive (93{\%}) and specific (88{\%}) identification of CIN2/CIN3+ and may serve as a critical biomarker for cervical-cancer screening. Future efforts will focus on further refinements to enhance analytic sensitivity and specificity of our proposed test, as well as on prototype development.",
keywords = "Africa, Cancer, Cervical, LMIC, Point-of-care",
author = "Mohammed, {Sulma I.} and Wen Ren and Lisa Flowers and Bartek Rajwa and Chibwesha, {Carla J.} and Parham, {Groesbeck P.} and Irudayaraj, {Joseph M.K.}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.7709",
language = "English (US)",
volume = "7",
pages = "18787--18797",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "14",

}

TY - JOUR

T1 - Point-of-care test for cervical cancer in LMICs

AU - Mohammed, Sulma I.

AU - Ren, Wen

AU - Flowers, Lisa

AU - Rajwa, Bartek

AU - Chibwesha, Carla J.

AU - Parham, Groesbeck P.

AU - Irudayaraj, Joseph M.K.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cervical cancer screening using Papanicolaou's smear test has been highly effective in reducing death from this disease. However, this test is unaffordable in low- and middle-income countries, and its complexity has limited wide-scale uptake. Alternative tests, such as visual inspection with acetic acid or Lugol's iodine and human papillomavirus DNA, are sub-optimal in terms of specificity and sensitivity, thus sensitive and affordable tests with high specificity for on-site reporting are needed. Using proteomics and bioinformatics, we have identified valosin-containing protein (VCP) as differentially expressed between normal specimens and those with cervical intra-epithelial neoplasia grade 2/3 (CIN2/CIN3+) or worse. VCP-specific immunohistochemical staining (validated by a point-of-care technology) provided sensitive (93%) and specific (88%) identification of CIN2/CIN3+ and may serve as a critical biomarker for cervical-cancer screening. Future efforts will focus on further refinements to enhance analytic sensitivity and specificity of our proposed test, as well as on prototype development.

AB - Cervical cancer screening using Papanicolaou's smear test has been highly effective in reducing death from this disease. However, this test is unaffordable in low- and middle-income countries, and its complexity has limited wide-scale uptake. Alternative tests, such as visual inspection with acetic acid or Lugol's iodine and human papillomavirus DNA, are sub-optimal in terms of specificity and sensitivity, thus sensitive and affordable tests with high specificity for on-site reporting are needed. Using proteomics and bioinformatics, we have identified valosin-containing protein (VCP) as differentially expressed between normal specimens and those with cervical intra-epithelial neoplasia grade 2/3 (CIN2/CIN3+) or worse. VCP-specific immunohistochemical staining (validated by a point-of-care technology) provided sensitive (93%) and specific (88%) identification of CIN2/CIN3+ and may serve as a critical biomarker for cervical-cancer screening. Future efforts will focus on further refinements to enhance analytic sensitivity and specificity of our proposed test, as well as on prototype development.

KW - Africa

KW - Cancer

KW - Cervical

KW - LMIC

KW - Point-of-care

UR - http://www.scopus.com/inward/record.url?scp=84975452182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975452182&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7709

DO - 10.18632/oncotarget.7709

M3 - Article

C2 - 26934314

AN - SCOPUS:84975452182

VL - 7

SP - 18787

EP - 18797

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -